OPHELIA - logo choice 2018_07_18.jpg

OPHELIA study

Observational study of pregnancy hyperglycaemia, endocrine causes, lipids, insulin and autoimmunity

The aim of the OPHELIA study is to help explain why some women develop high blood sugar (glucose) levels in pregnancy. 

Gestational diabetes (GDM) affects approximately 35,000 pregnancies in the UK every year and is associated with pregnancy complications affecting both mother and child. Although most cases of GDM are thought to occur due to pregnancy-hormone-induced insulin resistance, other processes may also contribute. For example, there is likely to be some women who have autoimmune involvement,  pre-pregnancy insulin resistance, insulin insufficiency and altered pregnancy hormone concentrations which may contribute to the disease process. In addition, a minority of women diagnosed with GDM will be actively developing early type 1 or type 2 diabetes, and these women are likely to have greater pregnancy-related risks. 

The aim of this study is to identify pathophysiological differences in women with GDM by measuring autoantibodies, insulin and hormone concentrations, and to assess how these differences might affect pregnancy outcomes. Women will be invited to participate after they are referred for  glucose testing in pregnancy with an oral glucose tolerance test (OGTT) and will have extra blood taken for research purposes during their visit. Data from biochemistry and obstetric databases will be linked and analysed anonymously to assess the effects upon pregnancy outcomes.


The OPHELIA study was approved by the research ethics committee and the health research authority (IRAS 238504; REC 18/LO/0477). 

 

Current status:
OPHELIA has been a really popular study and we have recruited around 900 women from our target of 1000. Recruitment is likely to continue to December 2022. OPHELIA is currently in active recruitment from the following hospital sites:
Ipswich Hospital

Thank you very much to mothers, babies and hospital teams from the following sites who have already made a huge contribution to the success of OPHELIA:
Peterborough City Hospital
Hinchingbrooke Hospital
Norfolk & Norwich University Hospital
Queen Charlotte's Hospital
Colchester Hospital
Lister Hospital, Stevenage
Ipswich Hospital


Dissemination activities:
OPHELIA data was used to help support the development of the Covid-19 diagnostic guidelines for the diagnosis of gestational diabetes during the pandemic. This very important work has enabled gestational diabetes diagnosis to continue (albeit in reduced form) during the pandemic despite the huge challenges to offering face-to-face healthcare. 


Data from the OPHELIA study was presented at:
The ATTD conference, 2021
Diabetes UK annual professional conference, 2021